Stem Cell Therapy in Duchenne Muscular Dystrophy

The Role of Autologous Bone Marrow Mononuclear Cell Therapy in Duchenne Muscular Dystrophy

Status

Withdrawn

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02241434

Enrollment

Registered

2014-09-16

Start date

2009-01-31

Completion date

2016-06-30

Last updated

2018-10-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Duchenne Muscular Dystrophy

Keywords

Duchenne muscular dystrophy, Autologous Bone marrow Mononuclear cell therapy, Stem Cells

Brief summary

The purpose of this study was to study the effect of stem cell therapy in patients with Duchenne Muscular Dystrophy.

Interventions

BIOLOGICALStem Cell

Intrathecal autologous bone marrow mononuclear cell transplantation

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

3 Years to 25 Years

Healthy volunteers

Inclusion criteria

* age group of 3-25 years * Duchenne muscular dystrophy diagnosed on the basis of clinical presentation

Exclusion criteria

* presence of respiratory distress * presence of acute infections such as Human Immunodeficient Virus/Hepatitis B Virus/Hepatitis C Virus * malignancies * acute medical conditions such as respiratory infection, fever, hemoglobin less than 8, bleeding tendency, bone marrow disorder, left ventricular ejection fraction \< 30% * pregnancy or breastfeeding

Design outcomes

Primary

Measure	Time frame
Manual Muscle Testing	1 year

Secondary

Measure	Time frame
Brooke and Vignos Scale	1 year

Countries

India

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026